The DOJ's declination to intervene is a significant de-risking event for Corcept, removing the most severe financial threat from this qui tam action. Monitor for any future developments in the relator's amended complaint, but the absence of government backing substantially weakens the plaintiff's case. The stock may re-rate higher as this overhang lifts.
CORT drugs
CORT drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $72.65entry
- T+1 · 6mo ago +3.08%α +2.68% · $74.89
- T+5 · 5mo ago +7.53%α +11.35% · $78.12
- T+20 · 5mo ago +24.17%α +25.17% · $90.21
- T+60 · 3mo ago +60.95%α +58.45% · $116.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Corcept disclosed that the DOJ, California Department of Insurance, and named Plaintiff States have all declined to intervene in a qui tam lawsuit filed by a former employee in February 2017 regarding the sale and promotion of Korlym. The relator served an amended complaint on June 2, 2026, and the company intends to vigorously defend. This removes the risk of government-backed prosecution, significantly reducing the potential liability exposure.
Key Facts
- DOJ, California Department of Insurance, and named Plaintiff States declined to intervene in qui tam action
- Lawsuit initiated February 2017 by former employee (Relator Stephen Elliott)
- DOJ had issued a subpoena in November 2021; company responded in full
- Relator served amended complaint on June 2, 2026
- Company intends to vigorously defend against all claims
Financial Impact
No specific financial exposure disclosed; DOJ declination removes government-backed treble damages risk, which could have been material relative to $7.6B market cap
Risk Factors
- Relator may still pursue the case independently without government support
- Amended complaint could introduce new allegations or theories of liability
- Discovery costs and management distraction from ongoing litigation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-254622 |
| Document: 0001193125-26-254622-index-headers.html | 0001193125-26-254622 |
| Document: 0001193125-26-254622-index.html | 0001193125-26-254622 |
| Document: 0001193125-26-254622.txt | 0001193125-26-254622 |
Track record
36 reports on CORT
7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +63.06% at T+60 after the Feb 24, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20262d ago Insider Cluster Neutral 2/10 Entry $73.87 Now $69.22 −6.29% settles Dec 15
- Nov 10, 20265d ago 144 Neutral 2/10 Entry $74.53 Now $69.22 −7.12% settles Dec 10
- Nov 4, 202611d ago Insider Cluster Neutral 2/10 Entry $71.63 Now $69.22 −3.36% settles Dec 4
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $79.22 Now $69.22 −12.62% settles Dec 3
- Nov 2, 202613d ago Institutional Cluster Bearish 4/10 Entry $81.93 Now $69.22 +15.51% settles Dec 2
- Oct 27, 202619d ago SC 13G/A Neutral 3/10 Entry $86.28 Now $69.22 −19.77% settles Nov 25
- Oct 5, 20265w ago Insider Cluster Neutral 3/10 Entry $119.57 to $81.93 Now $69.22 −42.11% ▼ −31.48% −28.30% vs SPY
- Sep 23, 20267w ago 8-K Neutral 3/10 Entry $112.94 to $116.28 Now $69.22 −38.71% ▲ +2.96% +2.27% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.50% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.75% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers